Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.5x - 1.7x | 1.6x |
| Historical Pb Multiple | 1.5x - 1.8x | 1.6x |
| Fair Value | €97.40 - €107.65 | €102.53 |
| Upside | 17.7% - 30.1% | 23.9% |
| Benchmarks | - | Full Ticker |
| Ipsen S.A. | - | ENXTPA:IPN |
| Merck KGaA | - | DB:MRK |
| Evolus, Inc. | - | DB:EVL |
| Mayne Pharma Group Limited | - | DB:HG6 |
| Orexo AB (publ) | - | OM:ORX |
| Sanofi | - | XTRA:SNW |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| IPN | MRK | EVL | HG6 | ORX | SNW | |||
| ENXTPA:IPN | DB:MRK | DB:EVL | DB:HG6 | OM:ORX | XTRA:SNW | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 16.5% | NM- | NM- | NM- | 14.0% | ||
| 3Y CAGR | -17.4% | -3.1% | NM- | NM- | NM- | -4.1% | ||
| Latest Twelve Months | -42.3% | 3.5% | 6.3% | 56.9% | -186.5% | 37.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 17.3% | 13.6% | -83.6% | -42.9% | -24.4% | 18.3% | ||
| Prior Fiscal Year | 18.7% | 13.5% | -30.5% | -172.9% | -20.1% | 12.3% | ||
| Latest Fiscal Year | 10.0% | 13.1% | -18.9% | -43.4% | -34.4% | 12.4% | ||
| Latest Twelve Months | 10.0% | 13.2% | -20.4% | -28.5% | -35.2% | 13.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 16.3% | 12.0% | -456.5% | -24.8% | -127.3% | 11.2% | ||
| Prior Fiscal Year | 17.2% | 10.7% | -666.9% | -53.8% | -101.5% | 6.8% | ||
| Latest Twelve Months | 8.9% | 9.7% | -609.5% | -23.8% | -684.0% | 8.2% | ||
| Next Fiscal Year | 19.0% | 12.1% | -3171.1% | -2.9% | 33.2% | 12.2% | ||
| Two Fiscal Years Forward | 17.4% | 12.2% | 287.0% | -2.0% | 30.4% | 12.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 2.4x | 2.2x | 2.2x | 1.0x | 1.2x | 2.3x | ||
| Price / LTM EPS | 24.6x | 16.9x | -10.9x | -3.5x | -3.4x | 16.4x | ||
| Price / Book | 2.1x | 1.6x | -92.8x | 0.9x | -4.4x | 1.3x | ||
| Price / Fwd Book | 1.8x | 1.5x | -122.2x | 0.9x | -4.2x | 1.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -92.8x | 0.9x | 2.1x | |||||
| Historical P/B Ratio | 1.5x | 1.6x | 1.8x | |||||
| Selected P/B Multiple | 1.5x | 1.6x | 1.7x | |||||
| (x) Book Value | 77,507 | 77,507 | 77,507 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | IPN | MRK | EVL | HG6 | ORX | SNW | |
| Value of Common Equity | 8,654 | 48,043 | 602 | 382 | 748 | 100,772 | |
| (/) Shares Outstanding | 82.6 | 434.8 | 64.5 | 81.2 | 37.0 | 1,218.2 | |
| Implied Stock Price | 104.80 | 110.50 | 9.34 | 4.70 | 20.25 | 82.72 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.16 | 1.78 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 104.80 | 110.50 | 8.05 | 2.64 | 20.25 | 82.72 | |
| Trading Currency | EUR | EUR | EUR | EUR | SEK | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.16 | 1.78 | 1.00 | 1.00 | |